Home > Boards > US OTC > Biotechs >

ImmunoCellular Therapeutics Ltd. (IMUC)

Add IMUC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/10/2019 7:54:33 AM - Followers: 179 - Board type: Free - Posts Today: 0



-Zero debt.
-Former NYSE biotech.
-41 million OS.
-$3.5 million in cash on balance sheet.
-Trading at a market cap of $800,000.
-Company being shopped by management for a merger/buyout (confirmed by IR as of 12/14/18)- with NO debt, all proceeds go to shareholders :) 
-Valuable cancer IP and a CLEAN shell for merger.
-October 15, 2018 PR:   "
ImmunoCellular may continue efforts to pursue opportunities for partnerships, licensing or sale of its anticancer assets and research programs, and monetization of the its dendritic cell-based and Stem-to-T-cell intellectual property  . . . . . . ."



ImmunoCellular Therapeutics continues to make significant progress in meeting important goals and positioning the company for success. We believe that our cancer vaccine platform has the potential to be transformative in the treatment of cancer, and to create value for all our stakeholders. Our goal is to build ImmunoCellular into a leading, independent commercial-stage cancer immunotherapy company.

Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:

- Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.
More than 80% of the final manufactured product consists of matured DCs.

- Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.

- Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.

- Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.

- Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.
- Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.

Company Information:

21900 Burbank, 3rd Floor
Woodland Hills, CA 91367

Phone: 818-992-2907



Technologies:   http://imuc.com/technology/

Press Releases:   http://imuc.com/press/





Transfer Agent:

U.S. Stock Transfer Corp.
Suite 200
Glendale, CA 91204-2991

 Investor Relations:

Gary Nash, CEOcast, Inc.

Tel: (212)732-4300
Email: IR@imuc.com







ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells.

Announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, a leading European contract manufacturing organization focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015

>>> What these CANCER vaccines could be worth


Investor Presentation -> http://files.shareholder.com/downloads/AMDA-1HS8HT/61684022x0x652321/5FD13B20-8F93-44CE-994E-D5515E5F30FC/IMI_Corporate_Overview.pdf 





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#5393   Doubt it. Looks like just about everyone BooDog 04/10/19 07:54:33 AM
#5392   I have an open question regarding this settlement? love to be rite once 04/10/19 04:25:55 AM
#5391   I have to find my hard copies first. BooDog 04/09/19 07:17:02 PM
#5390   Maybe you'll get some pocket change from the sidedraft 04/09/19 07:13:10 PM
#5389   Received a class action notice through A.B. Data BooDog 04/09/19 05:51:11 PM
#5388   I think if you already have a position BioGuy2014 02/27/19 10:08:14 AM
#5387   Yup - still here, shares tucked away. SC777 02/15/19 05:08:00 PM
#5386   Tickimus watchimus is not necessary with IMUC. Waitin' Renee 02/15/19 10:24:51 AM
#5385   So many damn air shares here, they keep SC777 01/31/19 03:50:26 PM
#5384   Yes, this is being held down. SC777 01/29/19 10:55:39 AM
#5383   Paint down this morning Copper Hunter 01/29/19 09:43:03 AM
#5382   Being held down IMO. .08 cents SC777 01/28/19 10:01:47 AM
#5381   Gap to .20 SC777 01/25/19 12:23:14 PM
#5380   They have too much IP, assets to have Copper Hunter 01/25/19 11:57:09 AM
#5379   Let’s get this party started Copper Hunter 01/25/19 11:00:25 AM
#5378   Yes Indeed to .30... georgie18 01/22/19 02:55:16 PM
#5377   You got your wish, MAXM backed off :) SC777 01/22/19 02:48:21 PM
#5376   Didn't like the gap down so didn't buy Mean Weimaraner 01/18/19 12:00:08 PM
#5375   Not with whacktards hitting low .02s when we SC777 01/18/19 11:59:26 AM
#5374   I get that but his presence is a georgie18 01/17/19 05:09:48 PM
#5373   MAXM has not been active at all, I've SC777 01/17/19 05:01:24 PM
#5372   Would be nice to see Maxm leave the box... georgie18 01/17/19 04:28:50 PM
#5371   Looks good for tomorrow Mean Weimaraner 01/17/19 03:48:21 PM
#5370   IMUC...029...High of the day... georgie18 01/17/19 03:47:01 PM
#5369   Relax... georgie18 01/17/19 03:16:20 PM
#5368   OMG, stop slamming the bid - morons. SC777 01/17/19 03:09:46 PM
#5367   All part of the game we play... georgie18 01/17/19 11:39:40 AM
#5366   Whacktards holding it back. Who in SC777 01/17/19 11:05:31 AM
#5365   Yes Indeed... georgie18 01/17/19 10:21:53 AM
#5364   Large bids stacking ThisisStrange 01/17/19 09:33:58 AM
#5363   Any minute now! ThisisStrange 01/16/19 01:22:19 PM
#5362   IMUC...0289...Bids are stacked...Breaking the Double Top... georgie18 01/16/19 12:59:49 PM
#5361   IMUC...0269...Double Top here...lets see if it can break this... georgie18 01/15/19 03:02:35 PM
#5360   Thanks SC- appreciate the reply. BBstocks77 01/15/19 02:25:21 PM
#5359   I had an email exchange with IR a SC777 01/15/19 02:20:49 PM
#5358   Interesting technology, not sure how it compares to BBstocks77 01/15/19 02:19:45 PM
#5357   I agree, on watch for any type of news. BBstocks77 01/15/19 02:15:49 PM
#5356   What are the odds they get bought out? BBstocks77 01/15/19 02:15:12 PM
#5355   Been reading up on IMUC - might be BBstocks77 01/15/19 02:14:47 PM
#5354   They gapped it down, as expected. Still SC777 01/15/19 09:33:26 AM
#5353   IMMUC...0269...Coming out of the Oversold Position...as the Psar georgie18 01/15/19 06:21:41 AM
#5352   Cash value alone here is .08 cents. SC777 01/14/19 01:46:41 PM
#5351   IMUC...025...Oversold Chart ...adding on the Psar flip to georgie18 01/14/19 01:30:25 PM
#5350   Got some life in this bad boy, at SC777 01/14/19 01:22:51 PM
#5348   At bottom of their PR's. I emailed SC777 01/03/19 08:10:47 PM
#5347   Actually, are you looking at the wrong ticker? SC777 01/03/19 08:08:44 PM
#5346   What I/R.. Name please.. EmptyBones 01/03/19 08:01:39 PM
#5345   No longer needed - they got delisted from SC777 01/03/19 08:00:04 PM
#5343   Any idea where these shares are coming from? SC777 01/02/19 09:53:18 AM
#5342   They're either going to dissolve or get bought SC777 12/31/18 02:01:05 PM